The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences for their adipose-derived mesenchymal stem cell (HB-adMSC) treatment targeting relapsing-remitting multiple sclerosis (RRMS). This designation follows positive outcomes from a Phase II trial conducted by the Hope Biosciences Research Foundation (HBRF) in 2023 and 2024. The study, which involved high doses of pure mesenchymal stem cells administered intravenously to individuals with MS, led to the RMAT status.
During the Phase II trial at HBRF, 24 subjects were enrolled in a randomized, double-blind study where the treatment group received six intravenous infusions, each containing 200 million stem cells, totaling 1.2 billion cells over 32 weeks. Notably, the participants ranged from 18 months to over 90 years of age, showcasing the broad application of HB-adMSCs across various disease conditions. These treatments were conducted under both clinical studies and expanded access programs authorized by the US regulator, and also in compliance with the Federal Right to Try Act.
To qualify for RMAT designation, a therapy must exhibit initial clinical evidence of effectively addressing a serious or life-threatening condition with unmet medical needs. Hope Biosciences CEO Donna Chang expressed gratitude for being the first to receive RMAT designation for MS, emphasizing the potential of their technology in transforming autoimmune disease treatment. Chang highlighted the collaboration with HBRF, praising their expertise in cell therapy and patient-centered care, which has been crucial in advancing therapies for patients with debilitating conditions.
The RMAT designation signifies a significant milestone for Hope Biosciences, recognizing the potential impact of their HB-adMSC treatment in addressing the unmet medical needs of individuals with RRMS. The positive outcomes from the Phase II trial, which involved high doses of mesenchymal stem cells administered intravenously, have paved the way for Hope Biosciences to further advance their therapeutic approach for MS. This designation not only validates the efficacy of the treatment but also underscores the commitment of Hope Biosciences in developing innovative solutions for autoimmune diseases.
Key Takeaways:
– Hope Biosciences’ adipose-derived mesenchymal stem cell treatment for RRMS has been granted RMAT designation by the FDA.
– The Phase II trial conducted by the Hope Biosciences Research Foundation demonstrated promising outcomes, leading to the RMAT status.
– The collaboration between Hope Biosciences and HBRF has been instrumental in advancing cell therapy for autoimmune conditions, showcasing the potential of HB-adMSCs in transforming MS treatment.
– RMAT designation highlights the therapeutic potential of HB-adMSCs in addressing the unmet medical needs of individuals with RRMS.
Tags: regenerative medicine, cell therapy, gene therapy
Read more on pharmaceutical-technology.com